Rhizome AI GTM brain

Rhizome AI sells a cited regulatory research agent to life sciences teams developing drugs and devices.

category

AI regulatory intelligence

market profile

  • text: Drug and device teams need to interpret large and changing health authority document collections across jurisdictions.
  • text: Regulatory research competes with established intelligence databases, consultants and general AI tools.

personas

  • title: Regulatory affairs manager
    pains:
    • Finding relevant precedent across health authority documents is time-intensive
    • Answers need page-level evidence for review
  • title: Clinical development leader
    pains:
    • Trial design must account for differing FDA and EMA expectations
    • Teams need defensible evidence before regulator meetings
  • title: Biotech founder or regulatory consultant
    pains:
    • Small teams cannot dedicate large research teams to every regulatory question
    • Client or program decisions require source checking

icp

  • text: Biotech, pharmaceutical and medical device companies preparing research or regulatory submissions.
  • text: Small teams that need individual research access through enterprises requiring SSO and global authority coverage.
  • text: Regulatory and clinical teams researching FDA, EMA or other health authority precedents.

message pillars

  • text: Answer regulatory questions quickly.
  • text: Research broadly across documents.
  • text: Let reviewers trace claims to the page.
  • text: Offer accessible self-serve entry.

objections

  • objection: Can AI answers be trusted for regulatory decisions?
    response: Inspect underlying primary citations and independently review important conclusions; the homepage demonstration itself flags a source-coverage caveat.
  • objection: Does coverage include our regions?
    response: Check current authority and language coverage: the enterprise tier adds non-English authorities.
  • objection: Is it useful before an enterprise purchase?
    response: The free tier supports a limited real-question trial; compare results against a known research task.

competitors

  • name: Cortellis
    why: Life sciences intelligence suite named in Rhizome's comparison menu.
  • name: IQVIA Regulatory Intelligence
    why: Established regulatory intelligence alternative named by Rhizome.
  • name: ChatGPT
    why: General AI research alternative named in Rhizome's comparisons.

influencers

  • name: Chetan Mishra
    url: https://www.linkedin.com/posts/chemishra_6-months-ago-we-launched-rhizome-ai-to-help-activity-7490428848812109824-EAw_
    why: Founder shares product launch and coverage expansion.

keywords

  • FDA regulatory intelligence software
  • EMA regulatory research AI
  • FDA precedent search
  • biotech regulatory intelligence
  • clinical trial regulatory guidance
  • medical device FDA research

voice

  • confident and concise
  • research-led
  • accessible to nontechnical specialists

signals

  • text: A biotech is preparing an FDA meeting, IND or cross-jurisdiction trial strategy.
  • text: A regulatory team is expanding into new markets or comparing competing regulatory intelligence tools.

stack

  • Claude
  • ChatGPT
  • Copilot
  • Gemini
  • Perplexity

pricing

model: freemium
starting price: $0; paid Project tier $400/month

motion

hybrid

channels

  • LinkedIn
  • SEO
  • webinars
  • events
  • YC launch

confidence

high

Founders

  • name: Chetan Mishra
    title: Founder/CEO
    role: CEO
    bio: Building an agent platform for life sciences. Software engineer who's closed millions in enterprise deals - ran ai drug discovery platform at evolutionaryscale.com (raised 150m) - $7m closed as sales/solutions eng at instabase - co-author of a paper on the cover of science magazine (esm3) - first used vector db's in 2016 for image retrieval

Back to YC companies